Patents by Inventor Peter C. DeMuth

Peter C. DeMuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250134992
    Abstract: Disclosed herein are polyadenosine, polythymidine, polyguanosine, and/or polycytosine nucleic acid sequences, as well as interferon stimulatory DNA and immunostimulatory herpes simplex virus sequences, that may be conjugated to an albumin-binding domain, as well as pharmaceutically acceptable salts thereof. Furthermore, disclosed herein are methods for inducing an immune response in a subject, and methods of administering the polyadenosine, polythymidine, polyguanosine, and/or polycytosine nucleic acid sequences conjugated to an albumin-binding domain and an antigen to induce an immune response in a subject.
    Type: Application
    Filed: August 15, 2022
    Publication date: May 1, 2025
    Inventors: Peter C. DEMUTH, Martin P. STEINBUCK
  • Patent number: 12247052
    Abstract: The invention provides compounds including a CpG oligodeoxynucleotide sequence linked to a lipid by a linker and related compositions and methods. The invention features a compound consisting of the nucleotide sequence of SEQ ID NO:1, at its 5? end, bonded or linked by a linker to a lipid. Further, the invention features a method of treating a cancer in a human patient, comprising administering to the patient the compound. Further, the invention features a pharmaceutical composition including the compound and a pharmaceutically acceptable carrier. The invention features a kit including (I) the compound or a composition comprising the compound; and (ii) a protein comprising SEQ ID NO:2 or SEQ ID NO:3.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: March 11, 2025
    Assignee: Elicio Therapeutics, Inc.
    Inventors: Peter C. Demuth, Martin Steinbuck
  • Publication number: 20250009888
    Abstract: The invention provides compounds including a KRAS sequence that is linked to a lipid by a linker, and related compositions and methods.
    Type: Application
    Filed: September 11, 2024
    Publication date: January 9, 2025
    Inventors: Peter C. DEMUTH, Julian ADAMS, Martin P. STEINBUCK
  • Patent number: 12138301
    Abstract: The invention features a compound including a mutant KRAS sequence and a lipid, where the mutant KRAS sequence is conjugated to the lipid by a linker, and (i) the linker includes one or more polyethylene glycol blocks, (ii) the lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and (iii) the mutant KRAS sequence comprises or consists of the amino acid sequence selected from the group consisting of SEQ ID NOs:1-7 and 22-30. The invention features a composition including one or more compounds of the invention and a pharmaceutically acceptable carrier. The invention also features a method of treating a cancer in a human patient, the method including administering the composition to the patient. Further, the invention features a kit comprising the compound.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: November 12, 2024
    Assignee: Elicio Therapeutics, Inc.
    Inventors: Peter C. Demuth, Julian Adams, Martin Steinbuck
  • Publication number: 20240299450
    Abstract: The disclosure features amphiphilic ligand conjugates including a peptide or a ligand for a mucosal-associated invariant T-cell and a lipid and T cell receptor modified immune cells. The disclosure also features compositions and methods of using the same, for example, to stimulate proliferation of T cell receptor expressing cells.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 12, 2024
    Inventors: Dylan DRAKES, Peter C. DEMUTH
  • Publication number: 20230302108
    Abstract: The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).
    Type: Application
    Filed: February 28, 2023
    Publication date: September 28, 2023
    Inventors: Adrienne Li, Jackson Eby, Peter C. DeMuth
  • Publication number: 20230263882
    Abstract: Disclosed herein are CpG-amphiphiles and corona virus antigens (e.g., a coronavirus spike protein, a peptide thereof, or a nucleic acid sequence encoding the same) for use in inducing an immune response in a subject, and methods of administering CpG-amphiphiles and coronavirus antigens (e.g., a coronavirus spike protein, a peptide thereof, a coronavirus nucleocapsid protein, a peptide thereof, or a nucleic acid sequence encoding the same) to induce an immune response in a subject.
    Type: Application
    Filed: June 25, 2021
    Publication date: August 24, 2023
    Inventors: Martin P. STEINBUCK, Lochana M. SEENAPPA, Peter C. DEMUTH, Christopher M. HAQQ, Lisa MCNEIL
  • Patent number: 11623002
    Abstract: The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: April 11, 2023
    Assignee: Elicio Therapeutics, Inc.
    Inventors: Adrienne Li, Jackson Eby, Peter C. Demuth
  • Publication number: 20210060149
    Abstract: The invention features a compound including a mutant KRAS sequence and a lipid, where the mutant KRAS sequence is conjugated to the lipid by a linker, and (i) the linker includes one or more polyethylene glycol blocks, (ii) the lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and (iii) the mutant KRAS sequence comprises or consists of the amino acid sequence selected from the group consisting of SEQ ID NOs:1-7 and 22-30. The invention features a composition including one or more compounds of the invention and a pharmaceutically acceptable carrier. The invention also features a method of treating a cancer in a human patient, the method including administering the composition to the patient. Further, the invention features a kit comprising the compound.
    Type: Application
    Filed: March 1, 2019
    Publication date: March 4, 2021
    Inventors: Peter C. DEMUTH, Julian ADAMS, Martin STEINBUCK
  • Publication number: 20210040159
    Abstract: The invention provides compounds including a CpG oligodeoxynucleotide sequence linked to a lipid by a linker and related compositions and methods. The invention features a compound consisting of the nucleotide sequence of SEQ ID NO:1, at its 5? end, bonded or linked by a linker to a lipid. Further, the invention features a method of treating a cancer in a human patient, comprising administering to the patient the compound. Further, the invention features a pharmaceutical composition including the compound and a pharmaceutically acceptable carrier. The invention features a kit including (I) the compound or a composition comprising the compound; and (ii) a protein comprising SEQ ID NO:2 or SEQ ID NO:3.
    Type: Application
    Filed: March 1, 2019
    Publication date: February 11, 2021
    Inventors: Peter C. DEMUTH, Martin STEINBUCK
  • Publication number: 20200405834
    Abstract: The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).
    Type: Application
    Filed: January 27, 2017
    Publication date: December 31, 2020
    Inventors: Adrienne LI, Jackson EBY, Peter C. DEMUTH
  • Publication number: 20200345853
    Abstract: Provided herein are methods for stimulating an immune response to a target cell population or a target tissue in a subject by administering to the subject a composition comprising an amphiphilic ligand conjugate. Such an amphiphilic ligand conjugate can comprise a lipid, one or more cargos (e.g., a CAR ligand, a chimeric cytokine receptor target, a chimeric co-stimulation receptor target, a synNotch receptor target), and optionally a linker.
    Type: Application
    Filed: March 20, 2020
    Publication date: November 5, 2020
    Inventors: Darrell J. IRVINE, Peter C. DEMUTH
  • Publication number: 20180000906
    Abstract: The invention provides compositions including stabilized multilamellar lipid vesicles having crosslinked lipid bilayers (referred to herein as interbilayer-crosslinked multilamellar vesicles or ICMV) and including an ALK variant, pharmaceutical compositions containing vesicles (e.g., ICMV) including an ALK variant, and methods of treatment using such compositions. The invention provides compositions including stabilized multilamellar lipid vesicles with crosslinked lipid bilayers (e.g., an interbilayer-crosslinked multilamellar vesicle or ICMV) containing an Anaplastic lymphoma kinase (ALK) variant as an antigen that is associated with solid tumor cancers.
    Type: Application
    Filed: January 15, 2016
    Publication date: January 4, 2018
    Applicant: Vedantra Pharmaceuticals, Inc.
    Inventors: Adrienne LI, Jackson EBY, Peter C. DEMUTH
  • Publication number: 20170258738
    Abstract: The present invention provides, among other things, multilayer film coating compositions, coated substrates and methods thereof. In some embodiments, a structure, comprising a substrate and a multilayer film on the substrate, wherein the multilayer film comprises a release layer and one or more layer-by-layer films. In some embodiments, a structure comprising a microneedle substrate and a multilayer film coated on at least portion of the microneedle substrate, wherein the multilayer film comprises an agent for delivery.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 14, 2017
    Inventors: Peter C. DeMuth, Younjin Min, Darrell Irvine, Paula T. Hammond
  • Publication number: 20170246288
    Abstract: The present invention provides novel and inventive drug delivery systems with higher loading capability, a capacity to sequester high tumors levels of both hydrophobic and hydrophilic agents simultaneously, and longer release profiles. Some aspects of these delivery systems include compositions including stabilized multilamellar lipid vesicles having crosslinked lipid bilayers (referred to herein as inter-bilayer-crosslinked multilamellar vesicles or ICMV) covalently conjugated to an agent (e.g., an antigen).
    Type: Application
    Filed: September 11, 2015
    Publication date: August 31, 2017
    Applicant: Vedantra Pharmaceuticals, Inc.
    Inventors: Adrienne LI, Jackson EBY, Peter C. DEMUTH
  • Publication number: 20120027837
    Abstract: The present invention provides, among other things, multilayer film coating compositions, coated substrates and methods thereof In some embodiments, a structure, comprising a substrate and a multilayer film on the substrate, wherein the multilayer film comprises a first plurality of first units, each first unit comprising a protamine polypeptide. In some embodiments, a structure comprising a microneedle substrate and a multilayer film coated on at least portion of the microneedle substrate, wherein the multilayer film comprises an agent for release and a first plurality of first unit; each first unit comprising a first layer and a second layer, wherein the first layer and the second layer are associated with one another.
    Type: Application
    Filed: May 24, 2011
    Publication date: February 2, 2012
    Applicant: Massachusetts Institute of Technology
    Inventors: Peter C. DeMuth, Darrell J. Irvine, Raymond E. Samuel, Paula T. Hammond